Beyond CAR-T: New Engineered Immune Cell Types Head to the Clinic

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Race and Life Sciences: Where is the Healing?
When Raising Drug Prices Helps Patients
Next-gen Synthetic Biology Pushes Further Into Drug Discovery, mRNA and DNA on the Desktop
A Busy IPO Calendar: Forma, Repare, Progenity, Genetron